$CYTK on NASDAQ
March 04, 2024
Cytokinetics to Participate in March Investor Conferences
March 01, 2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
February 28, 2024
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
February 27, 2024
Cytokinetics Reports Fourth Quarter 2023 Financial Results
February 13, 2024
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
February 06, 2024
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 29, 2024
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
January 25, 2024
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
January 18, 2024
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
January 03, 2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 26, 2023
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
December 07, 2023
Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
December 01, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2023
Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
November 03, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 02, 2023
Cytokinetics Reports Third Quarter 2023 Financial Results
November 01, 2023
Cytokinetics to Participate in Upcoming Investor Conferences
October 23, 2023
Cytokinetics to Announce Third Quarter Results on November 2, 2023
October 19, 2023
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
October 06, 2023
Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
October 05, 2023
Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
October 03, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 02, 2023
Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
September 28, 2023
Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
September 07, 2023
Cytokinetics to Participate in Upcoming Investor Conferences
September 06, 2023
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
September 01, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023
Cytokinetics Reports Second Quarter 2023 Financial Results
August 01, 2023
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
July 27, 2023
Cytokinetics to Announce Second Quarter Results on August 3, 2023
July 05, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2023
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
June 02, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 01, 2023
Cytokinetics to Participate in Upcoming Investor Conferences
May 20, 2023
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
May 15, 2023
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
May 11, 2023
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
May 08, 2023
Cytokinetics to Participate in the JMP Securities Life Sciences Conference
May 04, 2023
Cytokinetics Reports First Quarter 2023 Financial Results
May 03, 2023
Cytokinetics to Hold Annual Meeting of Stockholders
May 01, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2023
Cytokinetics to Announce First Quarter Results on May 4, 2023
April 10, 2023
Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
April 03, 2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
March 27, 2023
Cytokinetics Releases Inaugural Corporate Responsibility Report
March 06, 2023
Cytokinetics to Participate in Upcoming Investor Conferences
- No Recent Filings Found.
